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Abstract
Illudin S is a natural sesquiterpene drug with strong anti-tumour activity. Inside cells, unstable active metabolites of illudin
cause the formation of as yet poorly characterised DNA lesions. In order to identify factors involved in their repair, we have
performed a detailed genetic survey of repair-defective mutants for responses to the drug. We show that 90% of illudin’s
lethal effects in human fibroblasts can be prevented by an active nucleotide excision repair (NER) system. Core NER enzymes
XPA, XPF, XPG, and TFIIH are essential for recovery. However, the presence of global NER initiators XPC, HR23A/HR23B
and XPE is not required, whereas survival, repair and recovery from transcription inhibition critically depend on CSA, CSB
and UVS, the factors specific for transcription-coupled NER. Base excision repair and non-homologous end-joining of DNA
breaks do not play a major role in the processing of illudin lesions. However, active RAD18 is required for optimal cell
survival, indicating that the lesions also block replication forks, eliciting post-replication-repair-like responses. However, the
translesion-polymerase DNA pol  is not involved.
We conclude that illudin-induced lesions are exceptional in that they appear to be ignored by all of the known global
repair systems, and can only be repaired when trapped in stalled replication or transcription complexes. We show that the
semisynthetic illudin derivative hydroxymethylacylfulvene (HMAF, Irofulven), currently under clinical trial for anti-tumour
therapy, acts via the same mechanism.
© 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The illudins are a family of natural sesquiter-
pene compounds with anti-tumour activity, originally
isolated from the mushrooms Omphalotus illudens
(jack-o-lantern) or Lampteromyces japonicus [1]. Al-
though many illudins are highly effective against var-
ious drug-resistant tumours both in vivo and in vitro,
the extreme cytotoxicity of these compounds in the
nanomolar range has severely restricted their practical
use in cancer therapy [2,3]. Recently semisynthetic
derivatives have been reported [4] with a strongly
Table 1
Properties of cells strains used
Human fibroblast
strain
Clinical symptoms Affected gene NER activity (%)a Repair pathway
affectedb
C5RO Normal control – 100 (deficient) –
XP25RO XP with neurological complications XPA <1 GG-NER + TC-NER
XPCS1BA XP/CS complex XPB (ERCC3) 5
XP6BE XP with neurological complications XPD (ERCC2) 25
XP42RO Mild XP XPF (ERCC4) 15–30
XP2BI XP XPG (ERCC5) 2
XP21RO XP 17 GG-NER
XP35RO XPC 15
XP4LE 20
XP2RO Mild XP XPE (DDB2) 61
CS3BE Cockayne syndrome CSA (ERCC8) ∼100 TC-NER
CS1AN Cockayne syndrome CSB (ERCC6)
Kps3 UVS syndrome Not cloned
XP1RO Mild XP (variant) RAD30A (POLH) ∼100 Translesion
DNA synthesis
XP30RO
94RD103 Non-photosensitive trichothiodystrophy Not cloned ∼100 NER = normal
Other cell strains Species (origin) Affected gene(s) Repair pathway affected
43-3B Chinese hamster ovary (CHO9) ERCC1 NER and crosslink repair
EM-9 Chinese hamster ovary (AA8) XRCC1 Base excision repair
V15B Chinese hamster ovary (V79B) Ku86 Non-homologous end-joining
XR-C1 Chinese hamster ovary (CHO9) DNA-PKcs
XR-1 Chinese hamster ovary (CHO-K1) XRCC4
HR23DKO Double-targeted mouse mutant
embryonic fibroblasts
HR23A and HR23B GG-NER
XPC– Targeted mouse embryonic fibroblasts XPC
DT40 (rad18) Chicken lymphoma (DT40) RAD18 Post-replication repair
a Measured as UV-induced unscheduled DNA synthesis (UDS).
b GG, global-genome; TC, transcription-coupled; NER, nucleotide excision repair.
improved therapeutic index [2,5,6] of which hydrox-
ymethylacylfulvene (HMAF, Irofulven) is currently
under clinical trial [7,8]. The tissue specificity and
tumour selectivity of the illudins has been attributed
to the presence of an energy-dependent system me-
diating transport into the cells [9] and subsequent
metabolic activation to an unknown reactive interme-
diate [10]. Inside the cells, strong inhibition of DNA
synthesis occurs, presumably caused by DNA damage
[2]. The requirement for prolonged incubation periods
of actively metabolising cells has hampered the iden-
tification of the responsible DNA adduct [11]. Early
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genetic studies using UV-sensitive rodent mutant cell
lines have indicated that nucleotide excision repair
(NER) is involved in the removal of illudin-induced
lesions [11]. However, contribution of other repair
pathways such as base excision repair (BER) or re-
combinational repair cannot be excluded as long as
the spectrum of lesions remains undefined.
In order to further investigate the mechanisms of
the extreme toxicity of the illudins, we have stud-
ied the toxicity and repair of illudin S lesions in
a variety of mammalian cell strains with known
defects in DNA repair processes, including NER,
BER, non-homologous end-joining (NHEJ) and
post-replication repair (PRR), (listed in Table 1).
Surprisingly, the data indicate that illudin-induced
DNA adducts are ignored by the global-genome re-
pair pathways (NER, BER and NHEJ), and can only
be processed when trapped in sites of stalled tran-
scription or replication forks. Transcription-coupled
NER and post-replication repair are the key processes
protecting cells to illudin S toxicity.
2. Materials and methods
2.1. Cell strains and culture conditions
Human fibroblast strains were cultured in Ham
F10 supplemented with 15% foetal bovine serum
and antibiotics. For Chinese hamster ovary cells a
1:1 mixture of Ham F10 and DMEM was used.
Chicken lymphoma cells were cultured at 39 ◦C in
HEPES-buffered RPMI1640, supplemented with 10%
inactivated calf serum and 1% chicken serum. Prop-
erties of the strains used in this study are summarised
in Table 1.
2.2. Agents
UV light of predominantly 254 nm was emitted
from a Philips TUV germicidal tube (fluence rate
0.3 W/m2). Stock solutions of illudin S (0.2g/ml
corresponding to 0.76M), isolated from O. illudens
as described [12] and HMAF (Irofulven, 1 mg/ml)
are fully stable at 4 ◦C [2] and diluted in culture
medium to the desired concentrations, immediately
prior to use. Radioactive nucleic acid precursors were
all purchased from Amersham Radiochemicals.
2.3. Cell survival assays
To avoid the time-consuming and laborious colony
assays of primary human fibroblasts, a simplified
approach was followed for measurement of cytotox-
icity. Sparse cultures (5 × 103 to 10 × 103 cells per
6 cm-dish, or 1× 103 to 2× 103 per 3 cm-dish) were
grown for 48 h and then exposed to illudin S or UV
and new medium was added. After 3–5 days of fur-
ther culture, when untreated control cultures were still
far from confluence, cells were pulse-labelled with
[methyl-3H]-thymidine (40–60 Ci/mmol, 5Ci/ml)
for 3 h in presence of 20 mM HEPES pH 7.3, to
obtain a measure for the number of proliferating
cells in each culture. After 30 min chase in unla-
belled medium, cells were rinsed, lysed in 0.25 M
NaOH and harvested. The incorporated radioactivity,
measured in a liquid scintillation counter, from four
control dishes and duplicate dishes for each exposure
were processed into mean ± S.E. points. As reported
earlier for human fibroblasts [13,14] as well as ro-
dent cells [11,15], this simplified protocol produces
highly reproducible UV-survival curves covering
three logs, and indistinguishable from those obtained
with classical colony assays. With a few standard
strains this was confirmed for illudin. Almost all
presented panels with survival curves are from sin-
gle representative experiments, containing negative
and positive controls to ensure reproducibility. Error
bars represent variability from triplicate of duplicate
dishes.
Chinese hamster cells were sparsely seeded in
dishes, exposed to various concentrations of illudin
and allowed to form colonies. Chicken lymphoma
cells were seeded at 106 cells per ml, exposed to
illudin for 24–48 h and counted or checked for thymi-
dine incorporation as above, immediately or after 1
day.
2.4. Unscheduled DNA synthesis
Coverslip cultures were exposed to 16 J/m2 of
UV light and cultured for 2 h in tritiated thymi-
dine as described [16]. In case of illudin S, cells
were incubated with 60 ng/ml in presence of
[methyl,1′,2′-3H]-thymidine (120 Ci/mmol, 5Ci/ml)
for 24 h. After radioactive labelling, all cultures were
fixed and processed for autoradiography as described
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[16], and silver grains were counted over at least 50
non-S-phase cells.
2.5. RNA synthesis inhibition and recovery
One-day-old fibroblast cultures in 3 cm-dishes were
prelabelled with [2-14C]-thymidine (50 mCi/mmol,
50 nCi/ml) for 16 h, exposed to illudin S for
3 h and cultured further. At various times, cells
were pulse-labelled (1 h) with [5,6-3H]-uridine
(38 Ci/mmol, 2Ci/ml), alkali-lysed and processed
for scintillation counting as described above. The ra-
tios of 3H to 14C are taken as a measure of overall
RNA synthesis [13].
Fig. 1. Illudin S and UV sensitivities of xeroderma pigmentosum strains. Cells were exposed to graded doses of UV (panel (B)) or illudin S
(panel (A) for 72 h-exposures and panel (C and D) for 24 h-exposures) and assayed for cell survival as indicated in the Section 2. Symbols:
() C5RO (normal), () XP25RO (XP-A), (	) XPCS1BA (XP-B), () XP21RO (XP-C), () XP6BE (XP-D), () XP2RO (XP-E), ()
XP42RO (XP-F), () XP2BI (XP-G), () XP1RO (variant). Error bars represent S.E. and are drawn wherever they exceed the symbol size.
3. Results
3.1. Core NER factors are required for repair of
illudin damage
Based on earlier experience with SV40-transformed
human fibroblasts [9] a treatment protocol of 72 h
with doses up to 1 ng/ml (0.26 nM) of illudin S was
chosen for the primary fibroblasts. In these condi-
tions, survival decreased exponentially with dose,
revealing a D10 value of about 1.1 ng/ml in normal
control cells and 0.12 ng/ml for fully NER-deficient
XP-A fibroblasts (see Fig. 1A). Thus, normal cyto-
toxicity was slightly higher than observed in a single
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SV40-transformed normal human fibroblast culture
[9]. The XP-A hypersensitivity ratio of 8–10 was
about the same as that obtained for UV-exposure,
with D10 values of about 1 and 10 J/m2 for XP-A and
normal cells, respectively (Fig. 1B). With shorter ex-
posure times, used in later experiments, higher doses
were required to produce the same lethality. An in-
verse relationship between time and dose was found
to exist between concentrations of 0.5 and 10 ng/ml at
least, with no significant change in relative sensitivity
of NER-defective XP-cells (Figs. 1A and C and 3A
and B, and data not shown).
In UV-sensitive fibroblasts with defective XPB,
XPD, XPF and XPG, other core enzymes of the
NER-pathway, the responses to illudin S were sim-
ilarly exaggerated, though less pronounced. In all
these cases, the hypersensitivity factors after exposure
to illudin S and UV irradiation were comparable (Fig.
1A, B and D), confirming the requirement of NER
for removal of illudin lesions, and suggesting similar
mechanisms of cytotoxicity.
3.2. Global-genome NER is dispensable
Unexpectedly, cells from XP group C, presented
a clear exception: an intermediate sensitivity to UV
(2.5–5) times (Fig. 1B), typical of XP-C strains [17]
contrasted with a fully normal survival after illudin
S exposure, a response found in three different hu-
man XP-C strains (Fig. 2A). In XPC-defective mouse
fibroblasts, known to be sensitive to UV as well
[18] this behaviour was confirmed (Fig. 2D). The
possibility existed that normal XP-C survival was
simply related to the protracted low dose treatment
protocol in combination with residual repair activity.
This explanation is highly unlikely since moderately
UV-sensitive XP-F cells with a residual NER level of
15–30% (similar to XP-C), were as sensitive to illudin
as they were to UV (Fig. 1D). In order to rigorously
exclude potential dosimetry effects, we confirmed
XP-C normalcy in a shorter (24 h) treatment protocol
(Fig. 2B). Furthermore, both XP-A and XP-C cells
retained their sensitivity to UV, when irradiation was
split in seven doses delivered over a 72 h period, in
order to mimic a low-dose-rate regimen similar to
illudin S (Fig. 2C). Consistent with the unexpected
behaviour of XP-C cells, UV-sensitive mouse fibrob-
lasts defective in both HR23A and HR23B proteins,
which can bind XPC protein and stabilise it (Ng et al.,
manuscript in preparation), were also as resistant to
illudin as normal mouse cells (Fig. 2D). In addition to
XP-C cells, also XP-E cells survived illudin exposure
normally (see Fig. 1D).
3.3. Illudin lesions are exclusively removed by
transcription-coupled NER
The enzyme complexes containing XPC and
XPE are responsible for the lesion-recognising
steps in the NER subpathway which repairs global
DNA damage. In XPE and XPC mutants preferen-
tial repair of actively transcribed DNA strands is
fully intact. Consistent deficiency (to varying de-
grees) in both global-genome repair (GG-NER) and
transcription-coupled repair (TC-NER) is a character-
istic feature of the other XP groups. (for a review, see
[19]). Our data suggest that only TC-NER is relevant
to illudin cytotoxicity. Therefore, cells from CS pa-
tients, known to have a selective defect in TC-NER,
were studied. CS-A and CS-B cells were seven and
nine times more sensitive to illudin S than two cell
strains with normal NER (see Fig. 3A). These re-
sponses to illudin are much more pronounced than
to UV (two and four times, respectively, data not
shown here. See [13,17]) and more near to fully
NER-deficient XP-A cells (see Fig. 3C). We found
exactly the same hypersensitivity pattern in cells
from patients with UV-sensitivity syndrome (UVS,
[20,21] see Fig. 3C), which also suffer from defective
TC-NER [22,23].
TC-NER is initiated at transcription forks stalled at
DNA lesions and allows completion of the transcript
after removal of the lesion (for overview see: [24]). To
study the inhibition and recovery of RNA synthesis,
the fibroblasts were exposed to illudin in a shortened,
3 h-exposure protocol, followed by a pulse-labelling
with tritiated uridine at various times (Fig. 3B). Initial
inhibition and subsequent recovery were evident in
normal and XP-C cells, but did not at all occur in
fully NER-defective XP group A. We conclude, that
illudin S-induced lesions indeed inhibit transcription
and require TC-NER to overcome this.
To investigate the actual rates of NER, we measured
illudin S-induced repair DNA synthesis by autoradio-
graphy (unscheduled DNA synthesis (UDS)). Even
in normal cells we found UDS to be very low: only
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Fig. 2. XPC/HR23 complex is dispensable for illudin survival. Survival curves obtained as in Fig. 1 after exposure to illudin S (panel (A)
for 72 h and panels (B and D) for 24 h) or to UV (panel C). Panel (A): three different XP-C strains tested against XP-A and normal cells.
Panel (B): XP-C survival after a 24 h exposure to illudin. Panel (C): extended UV-exposure protocol mimicking low dose rate; cells were
irradiated six times over a period of 72 h, summed up to the total doses indicated. Panel (D): illudin sensitivity of fibroblasts from KO
mice. Symbols: () C5RO (normal), () XP25RO (XP-A), () XP21RO (XP-C), (	) XP35RO (XP-C), (	) XP4LE (XP-C), () DKO
(HR23A/HR23B double mutant). Error bars represent S.E. and drawn wherever they exceed the symbol size.
after an exposure to relatively high doses (60 ng/ml
for 24 h, about 20 times higher than the D10 equiva-
lent) and an extended radioactivity incorporation pe-
riod during exposure (eight times longer than usually
applied with UV), significant UDS above background
could be measured in normal fibroblasts. Calculations
showed these levels to be at least 30 times lower than
what is common for a saturating dose of UV (16 J/m2),
consistent with the estimated low levels of lesions
[11]. The UDS we observed clearly represented NER,
since it was absent in XP-A cells (Fig. 3E). Despite
their defective GG-NER, XP-C cells showed approx-
imately the same level as normal cells, whereas in CS
cells, carrying the complementary defect in TC-NER,
only marginal levels of UDS were detected, compara-
ble to XP-A cells (Fig. 3E). This result was found in
both CS-A and CS-B and strongly contrasts with the
characteristic normal UDS levels after UV exposure
in these strains (see Fig. 3D and E) [17]. We conclude
that the observed (low) UDS activity of normal fibrob-
lasts exclusively represents TC-NER, with no signifi-
cant contribution of GG-NER.
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Fig. 3. Illudin survival depends on transcription-coupled NER. Panels (A and C): sensitivity of CS cells (panel (A)) and UVS (panel (C))
to illudin S. For comparison, dashed lines indicate the UV-sensitivities obtained with these cell strains, on a modified dose scale, such that
normal response curves of UV and illudin overlap. Panel (B): recovery of overall transcription after illudin exposure. Cells were prelabelled
with 14C-thymidine, exposed to 0 or 30 ng/ml of illudin S for 3 h, rinsed and pulse-labelled with 3H-uridine 1, 3 and 21 h later. Relative
rates of RNA synthesis are expressed as percentages of treated over mock-treated cells. Symbols in panels (A–C): () C5RO (normal),
() XP25RO (XP-A), () XP21RO (XP-C), () Kps3 (UVS), (	) CS1BE (CS-A), (	) CS1AN (CS-B), () 94RD103 (UV-resistant
trichothiodystrophy). Panels (D and E): unscheduled DNA synthesis induced by illudin S and UV, respectively. Averaged data plotted as
a percentage of responses in normal cells and compared to similarly plotted UDS-levels induced by UV.
Hydroxymethylacylfulvene (HMAF, Irofulven or
MGI-114) is a semisynthetic derivative of illudin S
[25], which is currently under clinical trial for tumour
therapy [4]. Fig. 4 shows that this agent is about 50
times less toxic to human fibroblasts than illudin S
(calculated D10 values 50 and 1 ng/ml per 72 h, re-
spectively). However, a 10 times increased sensitivity
in XP-A cells, combined with normal XP-C responses
were also found with HMAF (Fig. 4), suggesting that
this drug acts via the same mechanism as the other
illudins.
3.4. Involvement of other global repair pathways
If global illudin damage is not processed via the
NER pathway, the question remains whether other
global-genome repair pathways can take over. There-
fore we studied a number of Chinese hamster mutants
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Fig. 4. Cytotoxicity of HMAF. Human fibroblast survival curves
as determined in Fig. 1 after exposure to HMAF (Irofulven,
MGI-114). Symbols: () XP25RO (XP-A), () XP21RO (XP-C),
() C5RO (normal).
Fig. 5. Post-replication repair and cytotoxicity of illudin S. Panel (A): RAD18-deficient chicken lymphoma cells. Open symbols ()
represent mutant/WT sensitivity ratios obtained in seven separate survival experiments, under somewhat varying conditions (cell density,
time of treatment, etc). Closed symbol () represents the mean±S.D. of these tests. Panel (B): human XP-variant and normal fibroblasts,
exposed to illudin in absence or presence of 1.5 mM caffeine and cultured further (±caffeine) for survival determination. Curves are
normalised to values without caffeine, to indicate aspecific toxicity of caffeine (lower curves). The dashed line without symbols represents
sensitisation response obtained with XP-variant cells exposed to UV and caffeine (from a separate experiment). Symbols: () C5RO
(normal), () XP30RO (XP-variant).
with known defects in BER and NHEJ pathways
(all listed in Table 1). In colony-survival assays,
XRCC1-mutant BER-deficient cells as well as three
different NHEJ mutants (Ku86, DNA-PKcs, XRCC4)
were all as sensitive to illudin as their parental CHO
strains and/or mutant strains corrected with a normal
copy of their defective gene (data not shown). This
resistance is not specific to CHO cell metabolism,
since NER-deficient CHO mutants are hypersensitive
[11]. We conclude, that the two globally acting repair
pathways BER and NHEJ play no significant role
in illudin cytotoxicity. These data also suggest that
illudin lesions do not cause significant levels of DNA
breakage.
3.5. Illudin lesions presumably obstruct replication
forks
We have shown earlier, that in cells exposed to
illudin S, DNA synthesis is inhibited [2]. To investi-
gate the mechanism of DNA-replication interference
we measured the requirement of genes involved in
post-replication repair (PRR) pathways. In yeast
N.G.J. Jaspers et al. / DNA Repair 1 (2002) 1027–1038 1035
as well as human cells the RAD18/RAD6 protein
complex is involved in an early step of PRR [26–28].
Chicken DT40 lymphoma cells with two defective
RAD18 alleles are about two times hypersensitive to
UV (Yamashita et al., manuscript in preparation). For
unknown reasons, chicken lymphoma cells responded
to illudin in a highly variable manner, irrespective of
the different standardised growth conditions tested.
Fig. 5A summarises all our data, indicating that
RAD18-deficient cells are hypersensitive to illudin,
although experimental variability does not allow a
precise estimation of the extent.
Polymerase  (RAD30A) is one of the translesion
polymerases active in a downstream branch of the PRR
pathway (for overviews see: [29,30]). Absence of this
polymerase in XP-variant fibroblasts [31] did not or
hardly affect illudin toxicity (see Fig. 1D and 5B) Sen-
sitisation by caffeine, which is a characteristic feature
of UV-irradiated pol  mutants [32,33] was also not
observed with illudin (Fig. 5B). It follows that the
downstream translesion subpathway of PRR is either
not required or is accomplished by another translesion
polymerase (e.g. pol , pol  [34]) which we could not
investigate due to lack of mutants.
4. Discussion
Our present detailed data with cell strains from pa-
tients having xeroderma pigmentosum and from mice
with targeted NER mutations, confirm and extend an
early observation in CHO-cells, that NER can repair
illudin lesions [11,35]. The overall responses of the
non-transformed fibroblasts are highly reproducible
over different experiments and cell strains and are
found in the same order of magnitude as in relatively
resistant tumour cells in culture [9] which appear to
rule out large differences in transport and/or metabolic
capacities.
Total absence of NER (as occurring in XP-A cells)
renders human and mouse fibroblasts about 10 times
more sensitive to illudin S, the same enhancement
as seen with exposure to UV. This parallelism is
retained in other XP complementation groups with
NER defects of varying severity. Unexpectedly how-
ever, cells defective in components of the HR23/XPC
complex, present a notable exception, being normally
resistant to the drug. We conclude, that repair factor
XPC/HR23 is not used or not required for NER
of illudin-induced lesions. The XPC/HR23B pro-
tein complex is known to be selectively involved in
global-genome repair (GG-NER) [36], where it per-
forms an early function in lesion recognition [37,38]
and recruitment of subsequent core NER enzymes
[39]. Dispensability of GG-NER was further sup-
ported by the independence of XPE, a gene encoding
a component of the DDB complex, which plays a
complementary role in initiation of GG-NER [40].
According to current models [19,24,41] tran-
scription forks stalled at a lesion in the transcribed
strand form a structure that can initiate the so-called
transcription-coupled subpathway of NER (TC-NER)
without the need of damage recognition by the
XPC/HR23B and/or DDB complexes, but still re-
quiring all the other NER factors. We find here that
illudin lesions do interfere with transcription, and re-
quire TC-NER to recover. Cells defective in specific
TC-NER factors (CSA,CSB,UVS) are more sensitive
to illudin then they are to UV. The low levels of over-
all repair (measured as UDS) fully depend on these
TC-NER factors. Unfortunately, these low levels and
their prolonged induction times have hampered our
attempts to perform actual biochemical measurements
of transcribed strand-directed repair of actively ex-
pressed genes. Since in general, the rate of overall
removal of lesions by NER largely depends on the
affinity and levels of HR23/XPC [38] and DDB com-
plexes [42], our data are best compatible with the
notion that illudin lesions are recognised by GG-NER
with very low, undetectable affinity.
While NERable lesions appear to constitute about
90% of potentially lethal damage in fibroblasts, ac-
tively transcribed regions represent a much smaller
fraction of the genome. It appears that prolonged
stalling of transcription forks are the primary cy-
totoxic entity initiating the apoptotic sequence, as
suggested on other grounds earlier [43–45]. There-
fore, alternative or additional routes for global repair
of illudin lesions could also contribute to protection
against illudin. Our data with XRCC1-defective cells
indicate that the most common short-patch branch of
base excision repair [46,47] is probably not a candi-
date. The possibility that illudin-lesions lead to sig-
nificant levels of strand breakage is also considered
unlikely, since non-homologous end-joining defects
confer no sensitivity to illudin. Taken together, our
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data strongly suggest that illudin-lesions are ignored
by all of the known global repair pathways.
Illudin damage not only affects transcription com-
plexes, but inhibit DNA replication as well [2]. We
show that there is a strong requirement for RAD18, to
overcome such replication blockage. Chicken cells had
to be studied here, being the only RAD18-deficient
cells currently available. In parallel with TC-NER
defective cells (CS-A, CS-B, UVS), they are more
sensitive to illudin than to UV. The RAD18/RAD6
protein complex accomplishes an early step in
post-replication repair (PRR) [26–28]. A downstream
subpathway of PRR involves translesion synthesis by
one of a range of recently identified tolerant DNA
polymerases [30]. The fully normal responses of
XP-variant cells show that polymerase  (with prefer-
ence for UV CPD-lesions [48,49]) is not the enzyme
responsible for this action. However, the involvement
of other candidate translesion polymerases (e.g. pol ,
pol ) with different specificities [50] was not inves-
tigated here yet. A role in illudin cytotoxicity of the
alternative RAD5-dependent downstream subpath-
way of PRR [51] also remains to be checked. Finally,
we do not yet know whether there is involvement
of other replication-coupled repair modes, such as
recombination or mismatch-repair, in recovery from
illudin lethality. However, especially with respect to
recombinational repair such involvement seems likely,
since prolonged stalling of replication forks (e.g.
in RAD18-defective cells) is known to increase the
frequency of recombination [52]. Moreover, topoiso-
merase inhibitors, expected to compromise recombi-
national processing of stalled replication forks, were
shown to sensitise cells to illudins [25,53,54].
Information on the nature, chemical structure
and stability of illudin-induced DNA lesions, is
still lacking. Illudins probably do not produce in-
trastrand crosslinks, in view of moderate sensitivity
of ERCC1-deficient cells ([11] and data not shown).
Our data indicate that global repair pathways appear
not to act on the lesion, which is therefore unlikely
to cause major helix-distortion. To our knowledge,
such an unusual repair pattern has so far only been
found with a new class of agents producing adducts
exclusively in the minor groove of the DNA helix
[55]. The susceptibility to TC-NER was not investi-
gated by these authors, but the exquisite sensitisation
in RAD18 mutants which they observed, is fully
consistent with our data. Ecteinascidine 743 offers
another case of TC-NER-specificity for minor-groove
alkylation [56], although this lesion seems to poison
the NER process itself.
In conclusion, we show here that illudins, belonging
to a new and promising class of tumour-therapeutic
agents, produce a unique type of DNA lesion which is
largely ignored by global repair pathways. Only when
the lesions become trapped in transcription-complexes
or replication-forks, efficient repair mechanisms en-
sue, such as TC-NER or PRR. As a consequence, we
find that gene defects involved in these transcription-
and replication-coupled repair pathways confer highly
exaggerated sensitivity to the illudins, in comparison
to, e.g. UV light. Further studies on more compli-
cated endpoints such as mutagenesis and responses
in repair-deficient mice will be needed to expand on
this issue.
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